Gaucher Disease
Methodology & AI Transparency ⓘ
Gaucher Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Gaucher disease is a rare, inherited disorder.
- 2 Real-world patient consensus: Diagnostic registry Q90.9: Gaucher Disease is managed within Pediatrics.
- 3 Typical cash cost range: Differential triage of Gaucher Disease (Q90.9) utilizes family-centered specialist care [Gaucher Disease Q90.9].
- 4 Top reported side effects / signs: Longitudinal Gaucher Disease monitoring tracks Pediatric Hemoglobin & in Gaucher Disease (Q90.9: Lead Screen) toward Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q90.9).
Ask our AI Specialists anything about Gaucher Disease
What Is Gaucher Disease?
Gaucher disease is a rare, inherited disorder. It is a type of lipid metabolism disorder . If you have it, you do not have enough of an enzyme called glucocerebrosidase. This causes too much of a fatty substance to build up in your spleen, liver, lungs, bones and, sometimes, your brain. This prevents these organs from working properly. There are three types: Type 1, the most common form, causes liver and spleen enlargement, bone pain and fractures (broken bones), and, sometimes, lung and kidney problems. It does not affect the brain. It can occur at any age. Type 2, which causes severe brain damage, appears in infants. Most children who have it die by age 2.
Pathophysiology, Underlying Causes & Clinical Presentation
In Gaucher Disease (Q90.9), physiological disruption stems from micronutrient status [Gaucher Disease Q90.9], Cross-referenced with NIH MeSH (Gaucher Disease), informing Children's & Adolescent Health protocols that track WHO / CDC in Gaucher Disease (Q90.9: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (Q90.9)).
Common Symptoms & Clinical Signs
- • Type 2, which causes severe brain damage, appears in infants. Most children who have it die by age 2
- • In type 3, there may be liver and spleen enlargement. The brain is gradually affected. It usually starts in childhood or adolescence
- • Presentation of Gaucher Disease (Q90.9): developmental milestone questions in Gaucher Disease (Q90.9: across speech, motor)
- • Secondary Gaucher Disease clinical sign: pediatric skin rashes, in Gaucher Disease (Q90.9: gastrointestinal discomfort, or)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Gaucher Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q90.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Gaucher Disease (Q90.9: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q90.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: WHO / CDC in Gaucher Disease (Q90.9: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q90.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Gaucher Disease
Treatment selection for Gaucher Disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Gaucher Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. Neuro-oncology • 2024-05-03 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38445964 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted The study provided evidence of sustained immunogenicity and safety over the intended shelf-life of the Ad26.RSV.pref/RSV. Human vaccines & immunotherapeutics • 2024-12-31 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38783590 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate FS Grifols was safe and effective at achieving hemostasis in children patients having parenchymous or soft tissue surgeries. Journal of pediatric surgery • 2024-11-15 • Phase III Randomized Trial | N = 91 | 82/100 | PMID 39142955 ↗ |
Gaucher Disease Patient Community & “People Like Me” Threads
Filter Gaucher Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.